Opposing effects of acute versus chronic inhibition of p53 on decitabine’s efficacy in myeloid neoplasms

Decitabine is a DNA methyltransferase inhibitor and is considered a promising drug to treat myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) with p53 mutations. However, whether loss of p53 in fact increases the response of MDS/AML cells to decitabine remains unclear. In this study,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Sci Rep
Main Authors: Tamura, Moe, Yonezawa, Taishi, Liu, Xiaoxiao, Asada, Shuhei, Hayashi, Yasutaka, Fukuyama, Tomofusa, Tanaka, Yosuke, Kitamura, Toshio, Goyama, Susumu
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6547685/
https://ncbi.nlm.nih.gov/pubmed/31160638
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-019-44496-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados